The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Franson will help biopharma clients design a phased approach to inform and execute clinical development plans
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Subscribe To Our Newsletter & Stay Updated
